GLOBAL DRUG DISCOVERY MARKET FORECAST 2019-2027

The global drug discovery market is anticipated to grow at a CAGR of 8.54% between 2019 and 2027 and generate revenue of $83.2 billion by 2027. Drug discovery technologies are used for the synthesis and extraction of the target compound.

The following factors primarily drive the drug discovery market:

  • High prevalence rates of major health disorders
  • Implementation of drug discovery programs
  • Bioinformatics is the widely used drug discovery technology
  • Small molecule drug type constitutes the highest market share
  • Contract research organizations (CROS) are the fastest-growing end-user

The important drivers influencing the growth in the global drug discovery market is an aging population and technological advancement. Aging population has a major influence on patterns of health care spending in both developed and developing countries. The biopharmaceutical companies are rapidly advancing in the range of disciplines from genomics (e.g., CRISPR genome editing and machine learning) and target discovery to pre-clinical testing, thereby driving the drug discovery market.

The technologies and drug type are used extensively for various purposes. The High Throughput Screening (HTS) techniques provide the pharmaceutical/biotechnology industry, academic institutes, and contract research organization with an ability to screen such large libraries. Biochips are increasingly being used in the areas of biotechnological research, disease biomarker, and drug discovery. Combinatorial chemistry involves the generation of a large array of structurally diverse compounds. Nanotechnology-based resolutions in drug discovery are starting to produce considerable new perceptions into how biological systems function. Metabolomics is being increasingly used for the development of various biomarkers. Metabolomics analyses the different metabolites in the body. The growing usages of small molecule drugs for the treatment of chronic ailments are leading to the amplified demand for the drugs in the market. The drugs are used for biological treatments of autoimmune diseases, including treatments for rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn’s disease, and a range of related disorders.

Delay in product launches and poor access to the healthcare services in developing markets are the major factors hindering the drug discovery market. FDA regulation looks at the quality of drug product through carefully monitoring drug manufacturers’ compliance with current goods manufacturing practice regulations that take an immense time to approve, which leads to the delay of new product launches. Companies working on drug discovery are working in very limited geographies. Cognizance about syndromes such as genetic disorders, types of diabetes, mental health disorders, and other significant diseases is still very low. About 46% of the population is still undiagnosed.

The global drug discovery market segments include technology, drug type, service, and end-user.

Technology is segmented into:

  • High Throughput Screening
  • Combinatorial Chemistry
  • Biochips
  • Metabolomics
  • Pharmacogenomics and Pharmacogenetics
  • Nanotechnology
  • Bioinformatics
  • Spectroscopy
  • Other Technologies

Drug type is segmented into:

  • Small molecule drug
  • Biologic drug

Service is segmented into:

  • Drug Metabolism and Pharmacokinetics (DMPK) services
  • Chemical services
  • Biological services
  • Other pharmaceutical services

End user is segmented into:

  • Research institutes
  • Pharmaceutical companies
  • Contract research organizations (CROS)
  • Other end-user

This report shields the current market circumstances and the development scenarios of the global drug discovery market for 2019-2027. The report considered the income made through the sales of drug discovery for technology, drug type, service, and end-users to calculate the market size. The base year considered in the report is 2018.

Geographically, the global drug discovery market has been segmented into four major regions, which include:

The drug discovery market in North America is expected to hold the largest share by 2027 owing to possibilities of developing lifestyle-oriented sicknesses, the surge in healthcare expenditure and technological development in cardiology. North America constitutes a market share of approx. 45% during the forecast period. The United States is considered to be a lucrative market for cardiology surgeries due to the increase in lifestyle-oriented diseases and healthcare spending in the country. The United States has the world’s finest hospitals and clinics for cardiology surgeries and other heart-related procedures.

On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region for the drug discovery market. The Asian market is promising as various mobile healthcare companies have been planning to set up their business in Asian countries. Healthcare has developed one of India’s major sector, both in terms of employment & revenue. The business is developing at a noteworthy pace owed to its firming services, coverage and swelling spending by the private as well as public players. China has become one of the key nations in manufacturing medical devices all over the world.

The drug discovery market is segmented based on service, which is sub-divided into Drug Metabolism and Pharmacokinetics (DMPK) services, chemical services, biological services, and other pharmaceutical services. The market is also segmented based on the end-users, which includes research institutes, pharmaceutical companies, Contract Research Organizations (CROs), and other end users. DPMK service providers are incorporating customized, innovative approaches and advanced technologies, such as high throughput screening to provide decision-enabling high-quality data, with rapid turnaround times, to compete in the market. Biological services include the development of biochemical and cell-based assays, design and implementation of target-relevant assays, phenotypic functional assays, and biomarker assays. Research on the new medicine, the invention of a new drug, and improvement in the existing drugs are three main factors, which are propelling the growth of the pharmaceutical companies around the world. The CRO is a company, which provides support to the biotechnology, pharmaceutical, and medical industries in the form of research services outsourced on a contractual basis.

The key market players in the global drug discovery market are:

  • ASTRAZENECA PLC
  • BAYER AG
  • ELI LILY
  • JOHNSON AND JOHNSON
  • HOFFMANN-LA ROCHE LTD.

Company Profiles covers the analysis of important players. AstraZeneca (or ‘the company’) is engrossed in the development, manufacturing, and marketing the discovery of biological products and prescription pharmaceuticals in the therapeutic areas of infection, gastrointestinal, cardiovascular, neuroscience, oncology and respiratory. F. Hoffmann-La Roche Ltd (Roche or ‘the group’) is one of the leading healthcare groups, focused on the discovery and development, manufacturing and marketing of innovative therapeutic and diagnostic products. The group has its presence in several countries worldwide which encompasses Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

Key findings of the global drug discovery market are:

  • High prevalence rates of major health disorders
  • Implementation of drug discovery programs
  • Bioinformatics is the widely used drug discovery technology
  • Small molecule drug type constitutes the highest market share
  • Contract research organizations (CROS) are the fastest-growing end-user

TABLE OF CONTENTS
  1. RESEARCH SCOPE
    1. STUDY GOALS
    2. SCOPE OF THE MARKET STUDY
    3. WHO WILL FIND THIS REPORT USEFUL?
    4. STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    1. SOURCES OF DATA
      1. SECONDARY DATA
      2. PRIMARY DATA
    2. TOP-DOWN APPROACH
    3. BOTTOM-UP APPROACH
    4. DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    1. MARKET SUMMARY
    2. KEY FINDINGS
      1. HIGH PREVALENCE RATES OF MAJOR HEALTH DISORDERS
      2. IMPLEMENTATION OF DRUG DISCOVERY PROGRAMS
      3. BIOINFORMATICS IS THE WIDELY USED DRUG DISCOVERY TECHNOLOGY
      4. SMALL MOLECULE DRUG TYPE CONSTITUTES THE HIGHEST MARKET SHARE
      5. CONTRACT RESEARCH ORGANIZATIONS (CROS) ARE THE FASTEST-GROWING END USER
  4. MARKET DYNAMICS
    1. MARKET SCOPE & DEFINITION
    2. MARKET DRIVERS
      1. AGING POPULATION
      2. BRANDED DRUGS ARE OUTPERFORMING DUE TO HIGH COST COMPARED TO GENERIC DRUGS
      3. GROWING HEALTHCARE EXPENDITURE
      4. GLOBAL INCREASE IN LIFESTYLE ORIENTED DISEASES & FATALITIES
      5. TECHNOLOGICAL ADVANCEMENT
    3. MARKET RESTRAINTS
      1. DELAY IN PRODUCT LAUNCHES
      2. POOR ACCESS TO HEALTHCARE SERVICES IN DEVELOPING MARKETS
      3. SHIFT FROM BRANDED TO GENERIC DRUGS
    4. MARKET OPPORTUNITIES
      1. EXTENSIVE R & D FOR NEW PRODUCT LAUNCHES
      2. INCREASING DEMAND FOR SPECIALTY MEDICINES
      3. RISING INVESTMENT BY PHARMACEUTICAL COMPANIES IN IMPROVING BIG-DATA ANALYTICAL CAPABILITIES
    5. MARKET CHALLENGES
      1. COST BARRIER FOR LOCAL PEOPLE IN EMERGING ECONOMIES
      2. STRINGENT GOVERNMENT REGULATIONS
  5. MARKET BY TECHNOLOGY
    1. HIGH THROUGHPUT SCREENING
    2. BIOCHIPS
    3. BIOINFORMATICS
    4. PHARMACOGENOMICS AND PHARMACOGENETICS
    5. COMBINATORIAL CHEMISTRY
    6. NANOTECHNOLOGY
    7. SPECTROSCOPY
    8. METABOLOMICS
    9. OTHER TECHNOLOGIES
  6. MARKET BY DRUG TYPE
    1. SMALL MOLECULE DRUG
    2. BIOLOGIC DRUG
  7. MARKET BY SERVICE
    1. DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES
    2. CHEMICAL SERVICES
    3. BIOLOGICAL SERVICES
    4. OTHER PHARMACEUTICAL SERVICES
  8. MARKET BY END USER
    1. RESEARCH INSTITUTES
    2. PHARMACEUTICAL COMPANIES
    3. CONTRACT RESEARCH ORGANIZATIONS (CROS)
    4. OTHER END USER
  9. KEY ANALYTICS
    1. PORTERS FIVE FORCES MODEL
      1. THREATS OF NEW ENTRANTS
      2. THREAT OF SUBSTITUTE PRODUCTS
      3. BARGAINING POWER OF BUYERS
      4. BARGAINING POWER OF SUPPLIERS
    2. COMPETITIVE RIVALRY
    3. VALUE CHAIN ANALYSIS
    4. PESTLE ANALYSIS
    5. REGULATORY FRAMEWORK
    6. OPPORTUNITY MATRIX
  10. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. THE UNITED STATES
      2. CANADA
    2. EUROPE
      1. THE UNITED KINGDOM
      2. FRANCE
      3. GERMANY
      4. SPAIN
      5. ITALY
      6. REST OF EUROPE
    3. ASIA PACIFIC
      1. CHINA
      2. INDIA
      3. JAPAN
      4. SOUTH KOREA
      5. AUSTRALIA
      6. REST OF ASIA PACIFIC
    4. REST OF WORLD
      1. LATIN AMERICA
      2. MIDDLE EAST AND AFRICA
  11. COMPANY PROFILES
    1. 3M COMPANY
    2. ANTARES PHARMA
    3. ASTRAZENECA PLC
    4. BAYER AG
    5. BECTON, DICKINSON & COMPANY (BD)
    6. BOEHRINGER INGELHEIM
    7. ELI LILY
    8. HOFFMANN-LA ROCHE LTD
    9. GLAXOSMITHKLINE LLC
    10. JOHNSON AND JOHNSON
    11. MERCK & CO. INC.
    12. NOVARTIS
    13. PFIZER, INC.
    14. SANOFI

 

LIST OF TABLES

TABLE 1 GLOBAL DRUG DISCOVERY MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 2 FACT SHEET OF GLOBAL FATALITIES

TABLE 3 GLOBAL DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2019-2027 ($ MILLION)

TABLE 4 GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 5 GLOBAL BIOCHIPS MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 6 GLOBAL BIOINFORMATICS MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 7 GLOBAL PHARMACOGENOMICS AND PHARMACOGENETICS MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 8 GLOBAL COMBINATORIAL CHEMISTRY MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 9 GLOBAL NANOTECHNOLOGY MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 10 GLOBAL SPECTROSCOPY MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 11 GLOBAL METABOLOMICS MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 12 GLOBAL OTHER TECHNOLOGIES MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 13 GLOBAL DRUG DISCOVERY MARKET, BY DRUG TYPE, 2019-2027 ($ MILLION)

TABLE 14 GLOBAL SMALL MOLECULE DRUG MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 15 GLOBAL BIOLOGIC DRUG MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 16 GLOBAL DRUG DISCOVERY MARKET, BY SERVICE, 2019-2027 ($ MILLION)

TABLE 17 GLOBAL DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 18 GLOBAL CHEMICAL SERVICES MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 19 GLOBAL BIOLOGICAL SERVICES MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 20 GLOBAL OTHER PHARMACEUTICAL SERVICES MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 21 GLOBAL DRUG DISCOVERY MARKET, BY END USER, 2019-2027 ($ MILLION)

TABLE 22 GLOBAL RESEARCH INSTITUTES MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 23 GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 24 GLOBAL CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 25 GLOBAL OTHER END USER MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 26 GLOBAL DRUG DISCOVERY MARKET, BY REGION, 2019-2027 ($ MILLION)

TABLE 27 NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)

TABLE 28 EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)

TABLE 29 ASIA PACIFIC DRUG DISCOVERY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)

TABLE 30 REST OF WORLD DRUG DISCOVERY MARKET, BY REGION, 2019-2027 ($ MILLION) 

LIST OF FIGURES

FIGURE 1 GLOBAL DRUG DISCOVERY MARKET, BY REGION, 2019-2027 ($ MILLION)

FIGURE 2 GLOBAL DRUG DISCOVERY MARKET, SHARE BY TECHNOLOGY 2018 & 2027 (%)

FIGURE 3 GLOBAL DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2019-2027 ($ MILLION)

FIGURE 4 GLOBAL DRUG DISCOVERY MARKET, BY BIOCHIPS, 2019-2027 ($ MILLION)

FIGURE 5 GLOBAL DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2019-2027 ($ MILLION)

FIGURE 6 GLOBAL DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2019-2027 ($ MILLION)

FIGURE 7 GLOBAL DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2019-2027 ($ MILLION)

FIGURE 8 GLOBAL DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2019-2027 ($ MILLION)

FIGURE 9 GLOBAL DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2019-2027 ($ MILLION)

FIGURE 10 GLOBAL DRUG DISCOVERY MARKET, BY METABOLOMICS, 2019-2027 ($ MILLION)

FIGURE 11 GLOBAL DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2019-2027 ($ MILLION)

FIGURE 12 GLOBAL DRUG DISCOVERY MARKET, SHARE BY DRUG TYPE 2018 & 2027 (%)

FIGURE 13 GLOBAL DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2019-2027 ($ MILLION)

FIGURE 14 GLOBAL DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2019-2027 ($ MILLION)

FIGURE 15 GLOBAL DRUG DISCOVERY MARKET, SHARE BY SERVICE 2018 & 2027 (%)

FIGURE 16 GLOBAL DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES 2019-2027 ($ MILLION)

FIGURE 17 GLOBAL DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2019-2027 ($ MILLION)

FIGURE 18 GLOBAL DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2019-2027 ($ MILLION)

FIGURE 19 GLOBAL DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2019-2027 ($ MILLION)

FIGURE 20 GLOBAL DRUG DISCOVERY MARKET, SHARE BY END USER 2018 & 2027 (%)

FIGURE 21 GLOBAL DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2019-2027 ($ MILLION)

FIGURE 22 GLOBAL DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2019-2027 ($ MILLION)

FIGURE 23 GLOBAL DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), 2019-2027 ($ MILLION)

FIGURE 24 GLOBAL DRUG DISCOVERY MARKET, BY OTHER END USER, 2019-2027 ($ MILLION)

FIGURE 25 PORTERS FIVE FORCE MODEL

FIGURE 26 GLOBAL DRUG DISCOVERY MARKET, REGIONAL OUTLOOK 2018 & 2027 (%)

FIGURE 27 THE UNITED STATES DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 28 CANADA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 29 THE UNITED KINGDOM DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 30 FRANCE DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 31 GERMANY DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 32 SPAIN DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 33 ITALY DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 34 REST OF EUROPE DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 35 CHINA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 36 INDIA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 37 JAPAN DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 38 SOUTH KOREA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 39 AUSTRALIA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 40 REST OF ASIA PACIFIC DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 41 LATIN AMERICA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

FIGURE 42 MIDDLE EAST AND AFRICA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)

Request For A Free Sample